Needham & Company LLC Reiterates "Hold" Rating for Gilead Sciences (NASDAQ:GILD)

Gilead Sciences (NASDAQ:GILD - Get Free Report)'s stock had its "hold" rating reiterated by equities researchers at Needham & Company LLC in a research report issued to clients and investors on Friday,Benzinga reports.

Several other equities research analysts also recently issued reports on the stock. Wells Fargo & Company raised their target price on shares of Gilead Sciences from $120.00 to $140.00 and gave the company an "overweight" rating in a research note on Wednesday, March 5th. JPMorgan Chase & Co. lifted their price objective on shares of Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a research report on Thursday, March 27th. Morgan Stanley increased their price objective on shares of Gilead Sciences from $123.00 to $130.00 and gave the company an "overweight" rating in a research report on Tuesday, March 11th. Oppenheimer upped their price target on shares of Gilead Sciences from $115.00 to $132.00 and gave the company an "outperform" rating in a research note on Tuesday, March 4th. Finally, Piper Sandler raised their price objective on shares of Gilead Sciences from $105.00 to $110.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 12th. Nine analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $109.43.

Gilead Sciences Stock Down 2.0 %

Shares of NASDAQ GILD traded down $2.13 during mid-day trading on Friday, hitting $104.21. The company had a trading volume of 7,644,956 shares, compared to its average volume of 7,515,113. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. The firm has a 50-day simple moving average of $109.19 and a two-hundred day simple moving average of $98.48. The company has a market capitalization of $129.76 billion, a PE ratio of 281.65, a price-to-earnings-growth ratio of 0.71 and a beta of 0.32. Gilead Sciences has a one year low of $62.07 and a one year high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. The company had revenue of $6.67 billion for the quarter, compared to analysts' expectations of $6.77 billion. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The business's revenue was down .3% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.32) EPS. On average, equities analysts expect that Gilead Sciences will post 7.95 EPS for the current year.

Insider Activity

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 137,676 shares of the company's stock in a transaction that occurred on Wednesday, February 12th. The shares were sold at an average price of $102.22, for a total value of $14,073,240.72. Following the completion of the transaction, the chief financial officer now directly owns 171,223 shares in the company, valued at approximately $17,502,415.06. This represents a 44.57 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders sold 302,785 shares of company stock valued at $30,540,875 over the last quarter. 0.27% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Smallwood Wealth Investment Management LLC bought a new stake in Gilead Sciences in the first quarter valued at approximately $25,000. Goodman Advisory Group LLC bought a new stake in shares of Gilead Sciences in the 1st quarter valued at $29,000. HHM Wealth Advisors LLC increased its position in shares of Gilead Sciences by 118.5% during the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock worth $26,000 after buying an additional 154 shares during the period. YANKCOM Partnership bought a new position in Gilead Sciences during the fourth quarter worth $28,000. Finally, Core Alternative Capital lifted its holdings in Gilead Sciences by 370.8% in the first quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock valued at $34,000 after buying an additional 241 shares during the period. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.